Media headlines about Teligent (NASDAQ:TLGT) have been trending somewhat positive recently, Accern reports. The research firm identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Teligent earned a news impact score of 0.03 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.0511547745725 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Several equities research analysts have commented on the company. Canaccord Genuity lowered Teligent from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $9.00 to $5.00 in a research report on Tuesday, November 7th. TheStreet lowered Teligent from a “c-” rating to a “d+” rating in a research report on Wednesday, November 1st. Finally, Zacks Investment Research upgraded Teligent from a “strong sell” rating to a “hold” rating in a research report on Friday, October 13th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $7.00.

Teligent (NASDAQ TLGT) traded down $0.18 during trading on Monday, reaching $3.87. The company’s stock had a trading volume of 454,900 shares, compared to its average volume of 470,850. The company has a current ratio of 3.28, a quick ratio of 2.71 and a debt-to-equity ratio of 2.23. Teligent has a 1-year low of $2.82 and a 1-year high of $9.54. The stock has a market cap of $206.66, a price-to-earnings ratio of -16.83, a PEG ratio of 77.40 and a beta of 1.34.

Teligent (NASDAQ:TLGT) last released its quarterly earnings data on Monday, November 6th. The company reported ($0.08) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.01) by ($0.07). Teligent had a negative return on equity of 6.51% and a negative net margin of 16.95%. The company had revenue of $13.65 million during the quarter, compared to analysts’ expectations of $19.12 million. During the same quarter in the prior year, the company posted $0.01 EPS. The company’s revenue for the quarter was down 15.5% on a year-over-year basis. sell-side analysts forecast that Teligent will post -0.2 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at

Teligent Company Profile

Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.

Insider Buying and Selling by Quarter for Teligent (NASDAQ:TLGT)

Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with's FREE daily email newsletter.